China Pharmaceutical: Notice on Convening the Second Extraordinary General Meeting of Shareholders in 2025
Announcement on the company\'s acquisition of related party assets
Notice on Convening the Second Extraordinary General Meeting of Shareholders in 2025
China Pharmaceutical: 2024 Annual General Meeting of Shareholders Meeting Information
2024 Annual General Meeting of Shareholders Meeting Materials
Announcement on the subsidiary\'s API obtaining the CEP certificate
Implementation status of the 2024 “Improve Quality and Efficiency, Focus on Rewards” Action Plan and the 2025 “Improve Quality, Increase Efficiency, and Focus on Rewards” Action Plan
Notice on convening the 2024 Annual General Meeting of Shareholders
Announcement on the calculation of asset impairment losses and credit impairment losses in 2024
Announcement on the launch of financial derivatives business in 2025
Announcement on the intention to sign a “Financial Services Agreement” and related transactions with General Technology Group Finance Co., Ltd.
Occupation of non-operating capital and other related capital transactions in 2024
2024 Internal Control Evaluation Report
Announcement on the launch of financial derivatives business in 2025
Announcement on matters relating to Henan General Performance Compensation
Report of the Audit and Risk Control Committee on the evaluation of the performance of accounting firms in 2024 and the performance of supervisory duties
Risk Assessment Report on General Technology Group Finance LLC
The company\'s assessment report on the performance of accounting firms in 2024
2024 Audit and Risk Control Committee Performance Report
Announcement on the subsidiary\'s drug passing the generic drug consistency evaluation